

ITONIS INC.

A NEVADA COMPANY

QUARTERLY REPORT

As of August 31, 2017

Item 1: The exact name of the issuer and its predecessors.

The exact name of the Issuer is Itonis, Inc.

Item 2: The address of its principal executive offices:

22951 Mill Creek Drive
Suite A
Laguna Hills, CA 92653
Phone: (949) 200-8887

Email: mark@itonisholdings.com

Websites: www.itonisholdings.com and www.emesyl.com

Facebook: <https://www.facebook.com/emesyl.spray/>

Item 3: Security Information.

A. Par or Stated Value for each class of Securities

Security Symbol: ITNS
CUSIP Number 465733103
Common Stock: 1,800,000,000 authorized, Par Value \$0.001
Preferred Stock: 5,000,000 authorized, Par Value \$0.001
NO CUSIP number for the preferred.

B. Number of shares or total amount of securities outstanding for each class of securities outstanding

Period end date: August 31, 2017

Authorized Shares: 1,800M Common Shares; 5M Preferred Shares

Outstanding Shares: 1,377,955,289 Common Shares; 500,000 Preferred Shares

Public Float: Approx 942,462,566

Number of Beneficial Shareholders: Approx 2

Total number of Shareholders: Approx 662

Period end date: August 31, 2016

Authorized Shares: 1,800M Common Shares; 5M Preferred Shares

Outstanding Shares: 1,502,155,289 Common Shares; 500,000 Preferred Shares

Public Float: Approx 1,018,861,540

Number of Beneficial Shareholders: Approx 2

Total number of Shareholders: Approx 662

Period end date: November 30, 2016 year end

Authorized Shares: 1,800M Common Shares, 5M Preferred Shares

Outstanding Shares: 1,502,155,289 Common Shares, 500,000 Preferred Shares

Public Float: Approx 569,631,717

Number of Beneficial Shareholders: Approx 1

Total number of Shareholders: Approx 662

Period end date: November 30, 2015 year end

Authorized Shares: 1,800M Common Shares, 5M Preferred Shares

Outstanding Shares: 1,062,955,289 Common Shares, 500,000 Preferred Shares

Public Float: Approx 569,631,717

Number of Beneficial Shareholders: Approx 1

Total number of Shareholders: Approx 662

C. Transfer Agent

Justeene Blankenship

Action Stock Transfer Corp.

2469 E. Fort Union Blvd.

Suite 214

Salt Lake City, UT 84121

(801) 274-1088

This Transfer Agent is registered under the Exchange Act. The regulatory authority of the Transfer Agent is the United States Securities and Exchange Commission.

Item 4: Issuance History

The following shares were issued during the Nine month period ending August 31, 2017 and the twelve month period ending November 30, 2016.

Common Stock

2015:

None after November 30, 2015.

2016:

- The Company issued 143,000,000 shares of common stock to related parties for services with a value of \$286,000.
- The Company issued 296,200,000 shares of common stock to related parties for services with a value of \$75,673.

2017:

- The Company cancelled 124,200,000 shares issued to officers.

Item 5: Financial Statements

(i) The appended financial statements are incorporated by reference.

(ii) The following financial statements are incorporated by reference.

- Balance Sheet for August 31, 2017 and 2016.
- Statement of Income for the years ended August 31, 2017 and 2016.
- Statement of changes in stockholders' equity as of August 31, 2017.
- Statement of cash flows for the year ended August 31, 2017.
- Financial Notes as of August 31, 2017.

Management's Discussion and Analysis of Plan of Operation**Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion and analysis should be read in conjunction with the financial statements and notes thereto included in this report. The statements contained in this report that are not purely historical are forward-looking statements which would include, but not be limited to, statements regarding our expectations, hopes, intentions or strategies regarding the future. Forward-looking statements include statements regarding: future product or product development; future research and development spending on our product development strategies, and are generally identifiable by the use of the words "may", "should", "expect", "anticipate", "estimates", "believe", "intend", or "project" or the negative thereof or other variations thereon or comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements (or industry results, performance of achievements) expressed or implied by these forward-looking statements to be materially different from those

predicted. The factors that could affect our actual results include, but are not limited to, the following: general economic and business conditions, both nationally and in the regions in which we operate; competition' changes in business strategy or development plans; our inability to retain key employees; our inability to obtain sufficient financing to continue to expand operations; and changes in demand for products by our customers.

Plan of Operation:

The Company had focused its acquisition and business development efforts in the homeopathic pharmaceuticals industry. During this reporting period, the Company has produced an inventory of its Emesyl® Nausea Relief homeopathic product for marketing and sale. Emesyl® was invented by Dr. Charles Hensley, Ph.D., who had created the Zicam® cold remedy. The Company offers Emesyl® Nausea Relief for purchase at www.Amazon.com and www.Emesyl.com.

The Company has also pursued a technological project revolving around the licensing of an e-check mobile app from MyECheck, Inc. Itonis is awaiting MyECheck, Inc.'s mobile app to facilitate point of purchase transactions in the medical marijuana, gambling and general retail sectors. Itonis' licensing rights are merely pending MyECheck's finalization and delivery of the app.

Management's Discussion and Analysis of Financial Condition and Results of Operations

The Company is presently focused on marketing its Emesyl® homeopathic anti-nausea product for retail sale. Presently, Emesyl® is available for sale at www.Amazon.com and www.Emesyl.com. The Company is engaged in efforts to expand all marketing and sales.

The Company is also positioning itself to receive the final mobile app from MyECheck, Inc. The companies have been in communications to coordinate the delivery of the mobile app to Itonis, Inc.

Results of Operations:

Itonis is a development stage company. The operating expenses occurred during the quarter ended August 31, 2017 and 2016 were \$45,380 and \$418,069, respectively for a decrease of \$372,689.

In August 2012, the Company launched a new Itonis Pharmaceuticals division headed by Dr. Charles Hensley, Ph.D. to produce and market over the counter and prescription homeopathic preparations to treat both common ailments and chronic

diseases. Emesyl® is available for purchase at www.Amazon.com and www.Emesyl.com.

Since then, the Company has organized its Itonis Holdings, Inc. subsidiary to own and manage the entirety of the Emesyl® nausea relief product line. Dr. Hensley has fully assigned all the patent rights in Emesyl® nausea relief to Itonis Holdings, Inc.

In March 2014, the Company signed a licensing agreement with MyECheck, Inc. for the Company to implement a mobile app for point-of-purchase sales transactions in the medical marijuana, gambling, and general retail sectors. The Company is awaiting the final delivery of the app from MyECheck, Inc.

Off-Balance Sheet Arrangements

There are no off balance sheet arrangements.

Legal Proceedings

First Capital filed a claim against Itonis in Miami Dade County, Florida on January 12, 2012 for breach of contract relating to an agreement entered into for shareholder relations. Itonis was not served and therefore did not respond. A default judgment was entered into against Itonis on March 6, 2012. The Company is not aware for further activities in the matter.

Item 6 Issuer's Business, Products and Services

A. a description of the issuer's business operations;

The Company operates as a holding company and has embarked upon an aggressive plan to acquire high growth entrepreneurial companies that have established or are expected to establish themselves as leaders and successful enterprises in various market niches.

B. Date and State of Incorporation;

The issuer is a Nevada corporation incorporated on July 5, 2005.

C. the issuer's primary SIC code:

<i>Primary</i>	<i>6719</i>
<i>Secondary</i>	<i>6141</i>

D. the issuer's fiscal year end date;

November 30.

E. principal products or services, and their markets;

In August 2012, the Company launched a new Itonis Pharmaceuticals division headed by Dr. Charles Hensley, Ph.D. to produce and market over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company has launched the retail sale of the Emesyl® nausea relief product, and is awaiting delivery of inventory from its manufacturer. The Company has identified the market for its Emesyl® product line as the general public who suffers from nausea.

Since then, the Company has organized its Itonis Holdings, Inc. subsidiary to own and manage the entirety of the Emesyl® nausea relief product line. Dr. Hensley has fully assigned all the patent rights in Emesyl® nausea relief to Itonis Holdings, Inc.

In March 2014, the Company signed a licensing agreement with MyECheck, Inc. for the Company to implement a mobile app for point-of-purchase sales transactions in the medical marijuana, gambling, and general retail sectors. The Company is awaiting the final delivery of the app from MyECheck, Inc.

Item 7 Issuer's Facilities

The Company's corporate headquarters are located in approximately 2,383 square feet of leased office space in Laguna Hills, California pursuant to a lease that expires in August 2018. In the opinion of management, the Company's current space is adequate for its operating needs.

Item 8 Officers, Directors and Control Persons

A. Officers, Directors and Control Persons. In responding to this item, please provide the following information for each of the issuer's executive officers, directors, general partners and control persons, as of the date of this information statement.

A. Officers and Directors

The Management of the Issuer is described in detail and incorporated herein by reference to financial statements filed with the pink sheets.

Mark Cheung, CEO/President and Director.

Business Address: 22951 Mill Creek Drive, Suite A, Laguna Hills, CA 92653.

Employment History: (Apr 2002 – present) Attorney. Mr. Cheung has more than 20 years of business law and entrepreneurial experience in the legal fields of business litigation and appeals. He has been a name partner at his Irvine, California law firm that has handled numerous business litigation and intellectual property matters, including a trademark case that ended favorably in the U.S. Supreme Court. Through years of litigation matters, Mr. Cheung has confronted unprecedented business operational disputes and relationship issues, providing industry opportunities to enhance and apply problem-solving skills at all levels.

(Jan 2005 – 2017) Adjunct Faculty, Chapman University School of Law.

Board Memberships/Affiliations: Board Member, Consumer Credit Counseling Service of Orange County (2001 – present), which is a non-profit consumer service organization.

Steve Pidliskey, Vice President/ Secretary

Business Address: 22951 Mill Creek Drive, Suite A, Laguna Hills, CA 92653.

Employment History: (Aug 1978 – Jan 2011) Project Executive – TSO Alliance Delivery, National Competency Center, Global Technology Services at IBM Corporation (last position held). Mr. Pidliskey has had a 32 ½ year career with IBM where he has held numerous management positions. He has been responsible for business functions that included regional sales operations, global customer delivery, service support, project management, product planning, complex solution development, and technical sales support.

Donald Jolly, Ph.D., Chief Financial Officer/ Treasurer

Business Address: 22951 Mill Creek Drive, Suite A, Laguna Hills, CA 92653.

Employment History: (Jan 2010 – present) Director of Hyperbaric Medicine at the Center for New Medicine. He operates the hyperbaric treatment and financial aspects of the Center, and also conduct hyperbaric research.

(July 1999 – Jan 2010) Director of Back to Health Program and Director of Hyperbaric Medical Department at the Whitaker Wellness Institute. His responsibilities included hyperbaric therapy orientation and treatment, patient education, and hyperbaric research.

(prior history) Mr. Jolly has more than 20 years' experience in the Finance Industry. He has served at both the board and executive levels within the banking community, holding numerous executive positions ranging from the Vice President of Marketing to the President/CEO of several California banks. His wide array of corporate and retail experience include all aspects of banking operations, loans, marketing, personnel, and customer relations. His founding of a local California bank provided him valuable experience in managing the early developments of a business.

Board Memberships/Affiliations: Chairman, Richard A. Neubauer Research Institute, a 501(c)(3) non-profit organization established to further research, medical improvements, and education in hyperbarics. Chairman, Holy Family Institute, a non-profit organization.

Sam Joudeh, Director

Business Address: 22951 Mill Creek Drive, Suite A, Laguna Hills, CA 92653.

Employment History:

(Jan 2011 – present) President of Sam's Tailoring.Com, Inc. He owns and operates an on-line virtual store for the retail sale of designer brand men's wear. This is an offshoot of his family-operated men's wear business that was originally established in 1950.

(1995 – 2011) President of Sam's European Tailoring, Inc. He owned and operated a retail men's wear store.

(1983 – 2011) President of Sam's Tailoring, Inc. He owned and operated a retail men's wear store.

(May 2000 – 2010) President of The Suit Gallery Five Star Men's Wear, Inc. He owned and operated a retail men's wear store.

Board Memberships/Affiliations: None other than his membership on the boards of his other businesses identified above.

B. Legal - Disclaimer History.

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other misdemeanor offenses);

None.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

None.

C. Beneficial Shareholders

<u>Name of Beneficial Owner</u>	Shares of Common Stock <u>Owned</u>	<u>%</u>
Mark Cheung	179,458,875	12%**

(** Mark Cheung has been authorized by the Board of Directors to hold a controlling block of 51% of the voting power in the Company.)

Item9 Third Party Providers

The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and disclosure:

- 1. Investment Banker:**
None.

2. **Promoters:**
None.
3. **Counsel:**
Owen Naccarato, Esq.
Naccarato & Associates
18881 Von Karman Avenue
Suite 1440
Irvine, CA 92612
(949) 851-9261
Owen@owenn.com
4. **Accountant or Auditor:**
Michael Berg, CPA
1562 Portola Drive
San Francisco, CA 94127
(415) 515-4090
5. **Public Relations Consultant:**
None
6. **Investor Relations Consultant:**
None
7. **Advisory:**
None

Item 10 Issuer's Certificate

I, Mark Cheung, certify that:

- 1, I have reviewed this quarterly disclosure statement of Itonis, Inc.
- 2, Based upon my knowledge, this disclosure statement does not contain an untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement, and
- 3, Based upon my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement

October 17, 2017

/s/ Mark Cheung

Mark Cheung
President

I, Donald Jolly, certify that:

1, I have reviewed this quarterly disclosure statement of Itonis, Inc.

2, Based upon my knowledge, this disclosure statement does not contain an untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement, and

3, Based upon my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement

October 17, 2017

/s/ Donald Jolly

Donald Jolly
Chief Financial Officer

Itonis Inc.
(formerly "Kenshou Inc.")
Financial Statements and Footnotes
For the Nine Months Ended
August 31, 2017

Itonis Inc.
(formerly "Kenshou Inc.")
Balance Sheets
(unaudited)

	August 31 and November 30,	
	2017	2016
Current assets		
Cash	\$ 6,347	\$ 9,689
Prepaid expenses	-	-
Other Assets	2,086	2,086
Total current assets	8,433	11,775
Fixed Assets	-	-
Inventory	30,427	32,720
Emesyl Patent	13,000	-
Capitalized License Fees	324,000	324,000
	324,000	324,000
Total assets	\$ 375,860	\$ 368,495
Liabilities and stockholders' deficit		
Current liabilities		
Accounts payable and accrued liabilities	\$ 4,090	\$ 5,978
Accounts payable - related parties	229,009	229,009
Derivative liability	1,560	2,520
Loan payable	705,841	651,817
Income taxes payable	4,800	4,800
Total current liabilities	945,300	894,124
Total liabilities	945,300	894,124
Stockholders' deficit		
Preferred stock; no par; \$.001 par; 5,000,000 authorized; and 500,000 and 0 issued and outstanding for the periods ended August 31, 2017 and November 30, 2016	500	500
Common stock; \$.001 par; 1,800,000,000 authorized; 1,377,955,289 and 1,502,155,289 issued and outstanding for the periods ended August 31, 2017 and November 30, 2016	1,377,955	1,502,155
Additional paid-in capital	13,619,013	13,494,313
Accumulated deficit	(15,566,908)	(15,522,597)
Total stockholders' deficit	(569,440)	(525,629)
Total liabilities and stockholders' deficit	\$ 375,860	\$ 368,495

The accompanying notes are an integral part of these financial statements.

Itonis Inc.
(formerly "Kenshou Inc.")
Statements of Operations
(unaudited)

For the Nine Months Ended August 31,

	2017	2016	
Revenue	\$ 3,822	\$ 450	
Cost of Goods Sold	2,293	-	
Gross Margin	1529	450	
OPERATING EXPENSES			
Legal and professional fees	0	1,800	
Executive compensation	0	361,584	
General and administrative	45,380	54,685	
Total operating expenses	45,380	418,069	
OTHER (INCOME) EXPENSE			
Interest expense	920	3,164	
(Gain) loss on derivative liability	(960)	1,920	
Total other (income) expense	(40)	5,084	
Net loss before taxes	(43,811)	(422,703)	
Income tax expense	0	0	
Net loss	\$ (43,811)	\$ (422,703)	
Basic loss per common share	(\$0.00)	(\$0.00)	
Basic weighted average common shares	1,346,905,289	1,143,955,289	

The accompanying notes are an integral part of these financial statements.

Itonis Inc.
(formerly "Kenshou Inc.")
Statements of Operations
(unaudited)

	For the Three Months Ended August 31,	
	2017	2016
Revenue	\$ 1,760	\$ 374
Cost of Goods Sold	1,056	\$ -
Gross Margin	704	\$ 374
OPERATING EXPENSES		
Legal and professional fees	0	0
Executive compensation	0	0
General and administrative	9,687	22,927
Total operating expenses	9,687	22,927
OTHER (INCOME) EXPENSE		
Interest expense	277	1,589
Gain on Debt Forgiveness	-	-
(Gain) loss on derivative liability	-	(200)
Total other (income) expense	277	1,389
Net loss before taxes	(9,260)	23,942
Income tax expense	0	0
Net loss	\$ (9,260)	\$ (23,942)
Basic loss per common share	(\$0.00)	(\$0.00)
Basic weighted average common shares	1,377,955,289	992,571,956

The accompanying notes are an integral part of these financial statements.

tonis Inc. (formerly "Kenshou Inc.")
Statement of Stockholders' Deficit
(unaudited)

	Preferred Stock		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Shares	Amount	Shares	Amount			
Balance as of November 30, 2016	500,000	\$ 500	1,502,155,289	\$ 1,502,155	\$ 13,494,313	\$ (15,522,597)	\$ (525,629)
Net Loss for period						(43,811)	(43,811)
Cancellation of Shares			(124,200,000)	(124,200)	124,200		
Balance as of August 31, 2017	500,000	\$ 500	1,377,955,289	\$ 1,377,955	\$ 13,618,513	\$ (15,566,408)	\$ (569,440)

The accompanying notes are an integral part of these financial statements.

Itonis Inc.
(Formerly “Kenshou Inc.”)
Cash Flow Statements
(unaudited)

For the Nine Months and year ended

	August 31, 2017	November 30, 2016
Cash flows from operating activities:		
Net loss	\$ (43,811)	\$ (442,038)
Depreciation	-	358
Issue of common stock to related parties	-	361,584
Adjustments to reconcile net loss to net cash in operating activities:		
Increase (decrease) in derivative liability	(960)	840
Changes in operating assets and liabilities		
Current Assets	-	-
Prepaid Expenses	-	-
Inventory	2,293	(14,720)
Intangible Assets	-	-
Accounts Payable	(1,888)	(2,336)
Accounts Payable Retated Party	-	17,831
Income Taxes Payable	0	800
Net cash used in operating activities	<u>(44,366)</u>	<u>(77,681)</u>
Cash flows from investing activities:		
Purchase of Emesyl Patent	<u>(13,000)</u>	-
Net cash used in investing activities	<u>(13,000)</u>	-
Cash flows from financing activities:		
Loans	54,024	85,100
Stock Refund		
Stock for Debt		
Executive Stock returned to Treasury		
Stock Returned by Paramount		
Shares Issued for Consulting Services	-	-
Sale of stock	-	-
Net cash provided by financing activities	<u>54,024</u>	<u>85,100</u>
Net change in cash	(3,342)	7,419
Cash, beginning of period	<u>9,689</u>	<u>2,270</u>
Cash, end of period	<u>\$ 6,347</u>	<u>\$ 9,689</u>
Supplementary disclosure of cash flow information:		
Cash paid for interest	<u>\$ 920</u>	<u>\$ 1,454</u>
Cash paid for taxes	<u>\$ -</u>	<u>\$ -</u>
Stock Issued for Services	<u>\$ -</u>	<u>\$ 361,584</u>

Itonis Inc.
(Formerly “Kenshou Inc.”)
Notes to the Financial Statements
(unaudited)

NOTE 1. DESCRIPTION OF BUSINESS AND ACCOUNTING POLICIES

Description of Business – Itonis, Inc. (formerly Kenshou Inc.) (the "Company" or "Itonis") was incorporated on July 5, 2005 as Kenshou Inc. under the laws of the State of Nevada. On December 2, 2005, the Company changed its name to Itonis Inc.

In August 2012, the Company launched a new Itonis Pharmaceuticals division headed by Dr. Charles Hensley, Ph.D. to produce and market over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company has launched the retail sale of the Emesyl® nausea relief product, and is awaiting delivery of inventory from its manufacturer. The Company has identified the market for its Emesyl® product line as the general public who suffers from nausea.

Since then, the Company has organized its Itonis Holdings, Inc. subsidiary to own and manage the entirety of the Emesyl® nausea relief product line. Dr. Hensley has fully assigned all the patent rights in Emesyl® nausea relief to Itonis Holdings, Inc.

In March 2014, the Company signed a licensing agreement with MyECheck, Inc. for the Company to implement a mobile app for point-of-purchase sales transactions in the medical marijuana, gambling, and general retail sectors. The Company is awaiting the final delivery of the app from MyECheck, Inc.

Use of Estimates and Assumptions - The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation - These financial statements present the balance sheets and the related statements of operations, cash flows and stockholders' deficit of Itonis, Inc.

Fiscal Periods – The Company's fiscal year-end is November 30.

Cash and Cash Equivalents - For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. The carrying value of these investments approximates fair value.

Itonis Inc.
(Formerly “Kenshou Inc.”)
Notes to the Financial Statements
(unaudited)

Inventory- The Company has capitalized \$31,483 in product costs related to Emesyl®.

Patent- The Company’s wholly-owned subsidiary, Itonis Holdings, Inc., acquired all rights to the patent for Emesyl™. Dr. Hensley has assigned all rights, title and interests in Emesyl to Itonis Holdings, Inc.

Capitalized License Fees- The Company obtained a license for a mobile payment transfer application from MyECheck, Inc. The \$324,000 cost of the license has been capitalized pending commencement of sales.

Accounts Payable-Related parties- Amounts have been advanced by third parties to fund the operations of the Company. The advances are non-interest bearing, unsecured, and due on demand. (See Note 4.)

Derivative liabilities – The Company is contractually obligated to issue 1,200,000 more shares than it currently has issued. The values of these shares were originally recorded at their fair market value to determine the cost basis of the underlying transaction. The share liabilities are revalued at the end of each reporting period and the liabilities are adjusted to reflect current market value. The change in fair value is reflected separately in the Company’s Statements of Operations. As of August 31, 2017 and November 30, 2016 the fair value of the obligated shares was \$1,560 and \$2,520, respectively.

Income Taxes - The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “*Income Taxes*”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Earnings (loss) Per Share - The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “*Earnings Per Share*”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were

Itonis Inc.
(Formerly “Kenshou Inc.”)
Notes to the Financial Statements
(unaudited)

dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

Fair Value of Financial Instruments - Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, requires disclosing fair value to the extent practicable for financial instruments that are recognized or unrecognized in the balance sheet. Fair value of financial instruments is the amount at which the instruments could be exchanged in a current transaction between willing parties. The Company considers the carrying amounts of cash, certificates of deposit, accounts receivable, accounts payable, notes payable, related party and other payables, customer deposits, and short term loans to approximate their fair values because of the short period of time between the origination of such instruments and their expected realization. The Company considers the carrying amount of notes payable to approximate their fair values based on the interest rates of the instruments and the current market rate of interest.

Recent Accounting Pronouncements-

The Company has evaluated recent pronouncements through Accounting Standards Updates “ASU” 2017-07 and believes that none of them will have a material impact on the Company’s financial position, results of operations or cash flows.

NOTE 2. GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of August 31, 2017, the Company has incurred cumulative net losses of over \$15,560,000. Under current operations the Company requires capital for its operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the company cannot continue in existence.

Itonis Inc.
(Formerly “Kenshou Inc.”)
Notes to the Financial Statements
(unaudited)

NOTE 3. RELATED PARTY TRANSACTIONS

Management of the Company has made non-interest bearing, unsecured, due on demand cash advances to the Company and has accrued amounts due an officer for services which total \$ 934, 841 as of August 31, 2017.

During 2016, the Company issued 439,200,000 common shares to related parties for services with a value of \$361,673.

On May 17, 2017, the Company cancelled 124,200,000 share issued to 3 officers for services with their agreement.

NOTE 4. LOANS PAYABLE

Through August 31, 2017, the Company had received \$ 705,841 in short-term loans from related parties. These loans are due on demand and are interest free. During this most recent quarter, \$ 53,524 of these notes we issued with a conversion feature that allows the notes to be exchanged for common shares at 75% of the market price upon conversion.

The Company has issued the following convertible promissory notes during 2016 and through this reporting period in 2017:

- \$1,860 convertible promissory note, dated February 29, 2016.
- \$21,500 convertible promissory note, dated February 29, 2016.
- \$19,000 convertible promissory note, dated May 31, 2016.
- \$900 convertible promissory note, dated May 31, 2016.
- \$28,000 convertible promissory note, dated August 31, 2016.
- \$9,999.96 convertible promissory note, dated August 31, 2016.
- \$7,011.99 convertible promissory note, dated November 30, 2016.
- \$16,600 convertible promissory note, dated November 30, 2016.
- \$4,023.98 convertible promissory note, dated February 28, 2017.
- \$7,500 convertible promissory note, dated February 28, 2017.
- \$24,000 convertible promissory note, dated May 31, 2017.
- \$18,500 convertible promissory note, dated August 31, 2017.

Itonis Inc.
(Formerly “Kenshou Inc.”)
Notes to the Financial Statements
(unaudited)

NOTE 5. STOCKHOLDERS’ DEFICIT

Preferred Stock:

The Company has authorized 5,000,000 shares of preferred stock

On June 4, 2012, the Board of Directors of the Company approved the designation of Series A preferred shares which provides voting rights equal to the greater of (i) One Thousand (1,000) votes for each share of Series A Preferred Stock or (ii) the number of votes equal to the number of all outstanding shares of Common Stock, plus one additional vote such that the holders of Series A Preferred Stock shall always constitute a majority of the voting rights of the Corporation.

500,000 shares of Preferred Shares were issued to related parties June 5, 2015.

Common Stock:

On July 6, 2015 shareholders of record holding over 50% of the issued and outstanding shares of the Company approved the increase in authorized shares from 1,000,000,000 to 1,800,000,000 shares. There were 1,377,955,289 shares of common stock outstanding as of August 31, 2017.

Share Transactions:

Common Stock

2016:

- The Company issued 143,000,000 shares of common stock to related parties for services with a value of \$286,000.
- The Company issued 296,200,000 shares of common stock to related parties for services with a value of \$75,673.

2017:

- The Company cancelled 124,200,000 issued to officers.

NOTE 6. INCOME TAXES

The provision for income taxes consists of approximately \$800 in State taxes for the year ended November 30, 2016.

Itonis Inc.
(Formerly “Kenshou Inc.”)
Notes to the Financial Statements
(unaudited)

Deferred tax assets are comprised of the benefits of loss carry forwards for the years ended the November 30, 2016 and 2015 of approximately \$174,000 and \$150,000, respectively. Losses prior to December 1, 2009 were incurred in different industries and in foreign jurisdictions and their use would be limited to offset federal and state income taxes. These losses would also be limited by the change of control provisions in Section 382 and 383 of the Internal Revenue Code.

Management has concluded that the use of these loss carry forwards would be severely restricted and the effect of these losses is not included in this report.

Deferred taxes arise from temporary differences in the recognition of certain expenses for tax and financial reporting purposes. As of August 31, 2017, the company had significant timing differences for tax reporting purposes for the non-cash recognition of liabilities due for committed shares in excess of authorized shares, shares issued for services, and shares issued for compensation. The expenses related to these liabilities are treated as permanent differences between financial and tax reporting.

At August 31, 2017, management determined that realization of these loss carry forward benefits is not assured and has provided a valuation allowance for the entire amount of such benefits,

ASC 740 clarifies the accounting for uncertainty in income taxes and prescribes a recognition threshold, measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. Under ASC 740, we are required to recognize in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure. Our policy is to record interest and penalties related to unrecognized tax benefits in income tax expense. There were no unrecognized tax benefits recorded as of August 31, 2017 and November 30, 2016.